194 related articles for article (PubMed ID: 38543313)
1. Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions.
Coates S; Bardhi K; Lazarus P
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543313
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions.
Bardhi K; Coates S; Chen G; Lazarus P
Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399297
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.
Nasrin S; Watson CJW; Bardhi K; Fort G; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1081-1089. PubMed ID: 34493601
[TBL] [Abstract][Full Text] [Related]
6. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids.
Mazur A; Lichti CF; Prather PL; Zielinska AK; Bratton SM; Gallus-Zawada A; Finel M; Miller GP; Radomińska-Pandya A; Moran JH
Drug Metab Dispos; 2009 Jul; 37(7):1496-504. PubMed ID: 19339377
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Action and Pharmacokinetics of Cannabis.
Chayasirisobhon S
Perm J; 2020 Dec; 25():1-3. PubMed ID: 33635755
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.
Qian Y; Markowitz JS
Drug Metab Dispos; 2022 Jul; 50(7):968-979. PubMed ID: 35512806
[TBL] [Abstract][Full Text] [Related]
9. The cross-reactivity of cannabinoid analogs (delta-8-THC, delta-10-THC and CBD), their metabolites and chiral carboxy HHC metabolites in urine of six commercially available homogeneous immunoassays.
Wolf CE; Pokhai AA; Poklis JL; Williams GR
J Anal Toxicol; 2023 Nov; 47(8):732-736. PubMed ID: 37602947
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.
Nadulski T; Sporkert F; Schnelle M; Stadelmann AM; Roser P; Schefter T; Pragst F
J Anal Toxicol; 2005; 29(8):782-9. PubMed ID: 16356335
[TBL] [Abstract][Full Text] [Related]
11. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
12. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol, ∆
Pigliasco F; Malaca S; Lo Faro AF; Tini A; Cangemi G; Cafaro A; Barco S; Riva A; Pisati A; Amadori E; Striano P; Tagliabracci A; Huestis MA; Busardò FP
Front Pharmacol; 2022; 13():1038754. PubMed ID: 36353497
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
[No Abstract] [Full Text] [Related]
15. In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
Qian Y; Wang X; Markowitz JS
Drug Metab Dispos; 2019 May; 47(5):465-472. PubMed ID: 30833288
[TBL] [Abstract][Full Text] [Related]
16. Determination of cannabinoids in hair: Indicators for illegal vs CBD-rich cannabis use.
Casati S; Angeli I; Bergamaschi RF; Ravelli A; Colombo G; Binelli G; Minoli M; Orioli M
Forensic Sci Int; 2022 Apr; 333():111237. PubMed ID: 35228140
[TBL] [Abstract][Full Text] [Related]
17. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.
Chau N; Elliot DJ; Lewis BC; Burns K; Johnston MR; Mackenzie PI; Miners JO
J Pharmacol Exp Ther; 2014 Apr; 349(1):126-37. PubMed ID: 24459244
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
19. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
20. Investigation of phase II metabolism of 11-hydroxy-Δ-9-tetrahydrocannabinol and metabolite verification by chemical synthesis of 11-hydroxy-Δ-9-tetrahydrocannabinol-glucuronide.
Hassenberg C; Clausen F; Hoffmann G; Studer A; Schürenkamp J
Int J Legal Med; 2020 Nov; 134(6):2105-2119. PubMed ID: 32808050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]